SCHEMBL972023

SCHEMBL972023

Fc1ncccc1-c1ccc(Br)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 2/20 0.47
MAPT P10636 4/20 0.47
DHODH Q02127 4/20 0.43
CYP11B1 P15538 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
CSNK1A1 P48729 1/20 0.39
CSNK1D P48730 1/20 0.39
GSK3B P49841 1/20 0.39
CSNK1G2 P78368 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 1/20 0.38
MKNK1 Q9BUB5 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
CYP2C19 P33261 2/20 0.37
GRIA2 P42262 2/20 0.37
CYP1A2 P05177 1/20 0.37
HTT P42858 1/20 0.37
NAPRT Q6XQN6 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3881160 0.83 CYP11B2 (0.50) CYP11B2MAPTDHODHCYP11B1MAOA
SCHEMBL3876408 0.81 DHODH (0.50) CYP11B2MAPTDHODHCYP11B1MAOA
SCHEMBL31051044 0.81 DHODH (0.50) CYP11B2MAPTDHODHCYP11B1MAOA
SCHEMBL18162732 0.80 MKNK1 (0.57) MAPTDHODHALDH1A1MAPK1MKNK1
SCHEMBL12947927 0.80 DHODH (0.48) CYP11B2MAPTDHODHCYP11B1MAOA
SCHEMBL24196449 0.80 CYP11B2 (0.47) CYP11B2MAPTDHODHCYP11B1MAOA
SCHEMBL18255779 0.80 CYP11B2 (0.47) CYP11B2MAPTDHODHCYP11B1MAOA
SCHEMBL22230844 0.80 CYP11B2 (0.47) CYP11B2MAPTDHODHCYP11B1MAOA
SCHEMBL3875252 0.80 CYP11B2 (0.55) CYP11B2MAPTDHODHCYP11B1MAOA
SCHEMBL29889660 0.79 MAPT (0.49) CYP11B2MAPTDHODHCYP11B1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7871982-B2 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-18 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed
EP-1970377-A1 LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 CYP11B2 1407/4885MAPT 3463/4885DHODH 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.